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OVERVIEW 
 
Ionizing radiation with ultra-high dose rates (>40 Gy/s), known as FLASH, has drawn 
great attention since its introduction in 2014
1
. It has been shown to markedly reduce radiation 
toxicity to normal healthy tissues while inhibiting tumor growth with similar efficiency as 
compared to conventional dose rate irradiation in pre-clinical models. Some believe that 
FLASH irradiation holds great promises and is perhaps the biggest finding in recent 
radiotherapy history. However, others remain skeptical about the replication of FLASH 
efficacy in cancer patients with concerns about technical complexity, lack of understanding 
of its molecular radiobiological underpinnings, and reliability. This is the premise debated in 
this month's Point/Counterpoint.  
 
Arguing for the Proposition is Peter G. Maxim, PhD. Dr. Maxim received his Dipl. Phys. 
(M.Sc.) in Applied Physics from the Technical University, Berlin, Germany and his Dr. rer. 
nat. (PhD) in Biophysics from Humboldt University, Berlin, Germany. He started his 
professional career in medical physics as a postdoctoral fellow at Stanford University where 
he was subsequently appointed as Assistant Professor. He is certified by the American Board 
of Radiology in Therapeutic Radiologic Physics and is currently an Associate Professor, 
Director and Vice Chair of Radiation Oncology Physics at Indiana University. His personal 
areas of emphasis are stereotactic ablative radiation therapy (SABR), four-dimensional 
computed tomography (4D CT), and the development of novel, and safe radiation therapy 
that addresses the major technical challenge of accurately and precisely treating moving 
targets and anatomy. Peter is interested in the management of interdisciplinary, science- and 
technology-oriented teams in health care and is actively developing next-generation 
radiotherapy technologies.  
 
Arguing against the propositions is Paul Keall, PhD. Dr. Keall is a National Health & 
Medical Research Council Senior Principal Research Fellow and Director of the ACRF 
Image X Institute at the University of Sydney.  His team of scientists and clinical partners 
develop and apply novel cancer imaging and targeted radiotherapy methods.  One of Dr. 
Keall’s research interests is motion management in radiotherapy: he chaired the TG264 , 
“Safe Clinical Implementation of MLC tracking.” and is currently chairing the update to 
TG76: “The management of respiratory motion in radiation oncology (TG324)”.  Dr. Keall 
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has published over 300 papers and has 18 awarded patents. He is a Fellow of AAPM and sits 
on the Editorial Board of Medical Physics.  
 
FOR THE PROPOSITION: Peter G Maxim, Ph.D. 
Opening Statement 
Ultra-high dose rate irradiation (in sub-second time scales) or “FLASH” (the term coined 
by Favaudon et al. in 2014
1
), has recently gained attention because of the surprising 
observation of markedly increased therapeutic index compared to conventional dose rate 
irradiation (in minutes) in preclinical studies of in vivo animal models. In fact, normal tissue 
sparing by FLASH has been described at least as far back as 1966 by Hornsey and Alper
2
, 
who attributed this finding to depletion of oxygen in tissues at very high dose rates
3
, but has 
been relatively dormant until the recent renaissance of interest.  
 
The increased therapeutic index of FLASH compared to conventional dose rate 
irradiation, or the “FLASH effect,” has now been reported in multiple preclinical models. 
Normal tissue sparing by FLASH of multiple organ systems including lung, brain, intestinal 
tract, and skin has been demonstrated in multiple mouse strains and even additional species 
(cat and mini-pig), while demonstrating an equivalent (and in some cases superior) 
tumoricidal effect relative to conventional dose-rate delivery in multiple in vivo tumor 
models
1,4-8
. Given the nascent state of the field, a large portion of experimental observations 
to date remain preliminary and unpublished, and many questions remain unanswered 
particularly with respect to mechanism. While there are data suggesting a fundamental 
physical-chemical effect, i.e., radiochemical depletion of oxygen at FLASH dose rates, 
modulation of inflammatory cytokines, e.g., TGF-, and differential immunologic responses 
between tumor and normal tissues, these could be downstream effects rather than 
independent mechanisms. Certainly, we have barely scratched the surface of potential 
mechanistic pathways. 
 
The FLASH effect is also incompletely characterized even from a phenomenological 
standpoint. Evidence to date suggests that a dose rate threshold of approximately 40 
Gray/second or higher is needed to produce the FLASH effect
1,6
. But the accelerator-based 
radiation delivery systems used for FLASH experiments to date produce pulsed radiation, and 
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there are many aspects of delivery speed, e.g., total dose and delivery time, dose per pulse, 
pulse timing structure, etc., that may be critical to the effect and have not been 
comprehensively evaluated, which poses an experimentally daunting combinatorial problem. 
 
To date, preclinical FLASH irradiation of small animals and small, superficial targets in 
larger animals has been possible using modifications of existing irradiation systems that are 
capable of producing FLASH dose rates when limited to small volumes (of up to a few cubic 
centimeters), including electron linear accelerators
9,10
, a synchrotron light source producing 
kilovoltage energy x-rays
5
, and certain proton accelerators
11
. 
 
All together, these data provide strong evidence that the observed FLASH effect across 
multiple species and organ systems is real, which makes this dramatic finding the biggest 
‘Newsflash’ in recent radiotherapy history. 
 
AGAINST THE PROPOSITION: Paul Keall, Ph.D. 
 
Opening Statement 
 
FLASH therapy is an interesting concept that is attracting scientists, clinicians and 
industry.  With the sobering findings of the Global Task Force on Radiotherapy for Cancer 
Control
12
, demonstrating the staggering worldwide need for radiation therapy, any technology 
that can reduce treatment times and enable more patients to be treated per machine is 
admirable. Faster treatments will also change the dose distribution to the lymphocytes in the 
circulating blood, potentially impacting the patient’s immune response. Understanding the 
biological mechanisms underpinning the effectiveness of FLASH therapy may provide new 
insights into current radiobiological theories. However, before jumping on the FLASH 
bandwagon, we should ask some questions: 
 
1. Does FLASH delivery technology exist for humans? No. And it will not exist for the 
foreseeable future. Ignoring VMAT, let’s assume that a state-of-the-art treatment 
would require 5-7 intensity modulated beams. As massive amounts of radiation are 
being delivered in a short time, real-time adaptive radiotherapy would be necessary to 
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ensure the delivered dose is close to the planned dose.  To achieve the benefits of 
FLASH and delivering the entire dose quickly, the following technologies – that 
currently don’t exist – need to be developed: 
 
a. A configuration of 5-7 FLASH beams to be delivered simultaneously.  
b. Fast FLASH intensity modulation. Currently limited by leaf speed, intensity 
modulation on a sub-second scale requires new technology to be built. 
c. Real-time FLASH adaptation. Given the higher requirements on motion 
management for stereotactic radiation therapy,
13
 it is even more important for 
the FLASH beam to be adapted in real-time to ensure the beam and the target 
are aligned.  
 
2. Will FLASH be cost effective? No. Given 5-7 beam lines are required, either 5-7 beam 
generators are needed, or technology analogous to electron CT would have to be 
developed. The Task Force
12
 concluded that radiation therapy needs are highest in 
low and middle income countries.  Therefore, FLASH is incompatible with global 
needs.  
 
3. Will treatment times be reduced with FLASH therapy? Possibly. However, the impact 
may be small. Current high dose treatments with dual-arc VMAT can be delivered in 
two minutes of a 15-minute time slot. The remainder of the time in the room is patient 
set-up, immobilization and pre-treatment imaging. Developments in real-time 
adaptive radiation therapy may reduce the need for complex immobilization and pre-
treatment imaging. Reducing the >80% of the time the beam is not on, rather than the 
<20% of the time the beam is on, will have a larger impact.  
 
 
4. Are the controls questionable in FLASH experiments? Sometimes. Creating FLASH 
beams that match conventional beams is challenging. It is difficult to change just one 
variable, the dose rate. For example, in one of the first in vivo FLASH studies,
14
 mice 
with lung tumors were treated with Cs-137 photons in the conventional arm, and with 
4.5 MeV electrons in the FLASH arm. The FLASH arm showed lower lung toxicity. 
However, is this difference explained by physics or biology? Cs-137 photons deliver 
higher doses outside of the tumor, whereas 4.5MeV electrons have lower surface dose 
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and higher central dose in mice. In another study, the results of square conventional 
beams were compared with FLASH circular beams, albeit of similar equivalent field 
size.
15
 Every FLASH study should be carefully reviewed to evaluate the impact of 
these differences, in addition to dose rate, on the results.   
 
In summary, FLASH is an interesting concept that has caught the imagination of many 
people. Am I on the FLASH bandwagon? No. I remain an interested spectator. 
 
Rebuttal: Peter G Maxim, Ph.D. 
I appreciate Dr. Keall’s insights and valid arguments in his opening statement. 
Dr. Keall stated that FLASH RT is currently not available for humans, and it will not 
exist in the foreseeable future either. It is true, as of today, FLASH has only been studied in 
preclinical settings and there are no published studies reporting on clinical translation. Will it 
not exist in the foreseeable future? I disagree.  
 
Recent advances in linear accelerator science and radiofrequency power generation and 
distribution technologies have led to prototypes of compact, high-efficiency linear 
accelerators suitable for producing high-energy x-rays (in the megavoltage energy range) or 
very high-energy electrons (exceeding 100 MeV energy) capable of treating large-volume, 
deep-seated targets at FLASH dose rates. In particular, investigators at Stanford University 
(Billy W Loo, Jr., MD, PhD), SLAC National Accelerator Laboratory (Sami G Tantawi, 
PhD), and Indiana University (Peter G Maxim, PhD), are engaged in a program to develop a 
medical linear accelerator system based on these technologies, called pluridirectional high-
energy agile scanning electronic radiotherapy (PHASER), designed to deliver highly 
conformal FLASH intensity-modulated radiation therapy to general radiation therapy 
targets
16
. 
 
The core enabling and technical innovations of PHASER-based FLASH include: (1) 
highly compact, economical, and power-efficient linear accelerator and radiofrequency (RF) 
power sources based on fundamentally new accelerator science able to produce hundred-fold 
greater beam output than conventional medical linacs; (2) a rapid RF power-distribution 
system that supplies an array of 16 stationary beamlines providing a full complement of non-
coplanar (conical geometry) beams for highly conformal radiotherapy without mechanical 
gantry rotation; (3) rapid electronically scanned highly intensity-modulated photon beams 
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from scanning an electron beam on a stationary target and collimator array, eliminating the 
need for mechanical collimator motion; and (4) integration of full ring diagnostic-
quality/speed multi-detector CT, sharing a common isocenter with the non-coplanar treatment 
beamlines. Besides providing position verification immediately before and during rapid 
treatment delivery, fast diagnostic-quality CT facilitates an efficient adaptive planning work 
flow in which a scan at the beginning of a treatment session can be used for plan adaptation, 
for example by rapid selection from a set of pre-calculated plan permutations or fully re-
optimizing, depending on time and computational tradeoffs
17
. Such a workflow would allow 
higher patient throughput and reduces treatment room utilization times. 
 
With respect to the cost-effectiveness of PHASER, compactness, power efficiency, and 
economical manufacturing are key design considerations and we anticipate the overall cost to be 
like that of conventional linacs, which makes PHASER the ideal technology for globally 
accessible curative cancer care. 
 
The motivation for developing this technology was to provide a fundamental solution to 
mitigating uncertainty due to organ motion, by combining rapid volumetric image-guidance 
and treatment delivery that could be completed faster than the time scale of physiologic 
motion. The same delivery speed would enable clinical evaluation of FLASH biological 
effects. 
 
In conclusion, FLASH promises to be a paradigm shift in curative radiation therapy with 
preclinical evidence of fundamentally improved therapeutic index. If this remarkable finding 
is translatable to humans, the switch to the PHASER technology will become mandatory. 
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Rebuttal: Paul Keall, Ph.D. 
My esteemed colleague has given a concise summary of the FLASH literature. When 
interpreting this literature, we should scientifically assess the FLASH results. For example, 
one of the articles referenced includes the claim that FLASH sparing has been demonstrated 
in cat and mini-pig species, the studies closest to human applications.
18
 We find that for the 
cat treatments, this was a single arm study, demonstrating only that radiation therapy works. 
In the mini-pig treatment, the FLASH vs. conventional results were positive. However, there 
was only one subject. The 95% confidence intervals on an n=1 study span 2.5% to 100%.  
 
One of the key drivers for FLASH are the biological changes. The studies to date have 
investigated only early effects of radiation. Even if these early changes are real, late effects 
may be better or worse with FLASH. As Darby has shown us with breast treatment,
19
 serious 
late effects continue more than 30 years after radiation therapy. What are the late effects with 
FLASH? Also, FLASH works against one of the four R’s of radiobiology, reoxygenation. 
Hypoxia is one of the biggest negative prognostic indicators of cancer treatment outcome.
20
 
Acute hypoxia varies on a timescale of minutes.
21
 With FLASH therapy, there is no time for 
changes in acute hypoxia to occur during treatment. Conventional therapy enables the 
delivery to be more biologically effective.   
 
With an analogy to another emerging technology, early radiomics studies were performed 
without independent test sets. Multiple hypotheses were tested without appropriate 
Bonferroni correction. There are now clear guidelines for radiomics studies.
22
 FLASH studies 
could benefit from such guidelines. To convince a scientist – and scientists should be 
convinced by data alone – a forward pathway for FLASH research and development is to: 
 
1. Perform controlled FLASH vs. conventional studies with the dose rate as the single 
controlled variable, 
2. Understand the radiobiology underpinning FLASH, 
3. Verify scientific findings independently, 
4. Appreciate the experimental limitations and quantify their estimated impact on the 
results, 
5. Solve, or define viable solutions for, all the technical problems necessary for human 
FLASH therapy listed in point 1 of my opening statement.  
 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
The scientists, authors, reviewers and editors involved with FLASH therapy need to 
carefully approach the subject and acknowledge the limitations of their studies. Overcoming 
these limitations will drive innovation. I will watch this space with interest.  
 
Finally, I leave you with the Oxford dictionary definition of FLASH: to shine in a bright 
but brief way.  
 
I would like to thank Helen Ball, Magdalena Bazalova-Carter and Amit Sawant for excellent 
and interesting input to this exciting topic. 
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